Harvard Apparatus Regenerative Technology (HRGN) Q1 2025 earnings summary

Executive summary

• Focused on regenerative medicine for gastrointestinal disorders and consumer health products, with clinical-stage esophageal implant and dietary supplements marketed in Asia.

• Ongoing phase 1 clinical trial for esophageal implant faces recruitment delays; all product revenue in the quarter from consumer health supplements.

• Substantial operating losses since inception; accumulated deficit reached $101.3 million as of March 31, 2025.

• Cash on hand of $1.7 million expected to fund operations into Q3 2025; additional capital needed to continue operations.

Financial highlights

• Product revenue was $45,000 for Q1 2025, down 21% from $57,000 in Q1 2024, all from consumer health products.

• Net loss for Q1 2025 was $1.66 million, an 18% improvement from $2.03 million in Q1 2024.

• Operating expenses decreased 17% year-over-year to $1.72 million, driven by lower R&D and sales/marketing costs.

• Gross margin declined due to shift from retail to wholesale pricing.

• Cash and cash equivalents were $1.73 million at March 31, 2025, down from $2.49 million at year-end 2024.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for 2025 and future years.

• Substantial doubt exists about ability to continue as a going concern without new financing by Q3 2025.

• Actively seeking additional funding through equity, debt, grants, or collaborations.